Abstract
We have tested a new ligand for peroxisome proliferator-activated receptor-gamma, GW7845, as an inhibitor of experimental mammary carcinogenesis, using the classic rat model with nitrosomethylurea as carcinogen. Rats were first treated with a single dose of nitrosomethylurea (50 mg/kg body weight, i.p.). Starting 1 week later, they were fed GW7845, at either 60 or 30 mg/kg of diet, for 2 months. This agent significantly reduced tumor incidence, tumor number, and tumor weight at both doses. This is the first report of the use of a ligand for peroxisome proliferator-activated receptor-gamma to prevent experimental breast cancer.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Animals
-
Anticarcinogenic Agents / therapeutic use*
-
Carcinogens
-
Drug Screening Assays, Antitumor
-
Female
-
Ligands
-
Mammary Neoplasms, Experimental / chemically induced
-
Mammary Neoplasms, Experimental / prevention & control*
-
Methylnitrosourea
-
Oxazoles / therapeutic use*
-
Rats
-
Rats, Sprague-Dawley
-
Receptors, Cytoplasmic and Nuclear / metabolism*
-
Tamoxifen / therapeutic use
-
Transcription Factors / metabolism*
-
Tyrosine / analogs & derivatives*
-
Tyrosine / therapeutic use
Substances
-
Anticarcinogenic Agents
-
Carcinogens
-
Ligands
-
Oxazoles
-
Receptors, Cytoplasmic and Nuclear
-
Transcription Factors
-
Tamoxifen
-
GW 7845
-
Tyrosine
-
Methylnitrosourea